



PASS — ALL SPECIFICATIONS MET

5 of 5 layers complete

■ L1
Identity

■ L2
Purity

■ L3
Net Peptide Content

■ L4
Sterility

■ L8
Fentanyl Screen

Sample & Vial Validation



Vial A: as received & analyzed

MORE VIEWS OF VIAL A



Vial A - right

Client	Be Still Vitality	Product	BPC-157/TB-4/Cartalax
Lot / Batch	T-DEA-0098	Label	BPC-157 10 mg + TB-500 10 mg + Cartalax
		Claim	10 mg
Matrix	lyophilized powder	Sample Count	1
Cap Color	Black	Crimp Color	Silver / Aluminum
Contents Color	White	Seal Intact	Yes
Condition	sealed, intact	Received	Sep 24, 2026
Sampling	client submitted		

Test Results

Test	Specification	Result	
Identity research screen	every declared component within ± 1 Da of its own theoretical mass	3 of 3 components confirmed	PASS
Purity research screen	each declared component at or above its own locked purity criterion	99.64%	PASS
Net Peptide Content research screen	each declared component within its own locked content criterion, at the declared ratio	31.73 mg	PASS
Sterility · Rapid PCR research screen	Rapid PCR screen	Target DNA not detected	PASS
Fentanyl Screen research screen	no fentanyl or analog at or above 1 ng/mg	none detected	PASS

Layer Results



1 Identity

LC-MS (ESI+)

3 of 3 components confirmed

each +/- 1 Da of its component mass

PASS

Component	Its criterion	Observed	Status
BPC-157	1419.556 Da · acceptance ± 1 Da · average	1419.686 Da	PASS
TB-500 (Thymosin B4)	4963.506 Da · acceptance ± 1 Da · average	4963.541 Da	PASS
Cartalax	333.297 Da · acceptance ± 1 Da · average	333.407 Da	PASS

2 Purity

RP-HPLC 214nm (USP 621)

99.64%

each component at or above its own locked purity criterion

PASS

Component	Its criterion	Observed	Status
BPC-157	Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31	99.64%	PASS
TB-500 (Thymosin B4)	Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31	99.33%	PASS
Cartalax	Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31	99.94%	PASS

3 Net Peptide Content

Quantitative HPLC vs reference std

31.73 mg

each component within its own locked content criterion, at the declared ratio

PASS

Component	Its criterion	Observed	Status
BPC-157	1 part · 9–11 mg · Declared blend recipe on the controlled Axiom catalog record for BPC-157/TB-4/Cartalax (component ratio 1); acceptance $\pm 10\%$ per Axiom SPEC-CONTENT-001	10.66 mg	PASS
TB-500 (Thymosin B4)	1 part · 9–11 mg · Declared blend recipe on the controlled Axiom catalog record for BPC-157/TB-4/Cartalax (component ratio 1); acceptance $\pm 10\%$ per Axiom SPEC-CONTENT-001	10.67 mg	PASS
Cartalax	1 part · 9–11 mg · Declared blend recipe on the controlled Axiom catalog record for BPC-157/TB-4/Cartalax (component ratio 1); acceptance $\pm 10\%$ per Axiom SPEC-CONTENT-001	10.4 mg	PASS

Observed ratio **BPC-157 1.00 : TB-500 (Thymosin B4) 1.00 : Cartalax 0.98** against declared **BPC-157 1.00 : TB-500 (Thymosin B4) 1.00 : Cartalax 1.00** · source Declared blend recipe on the controlled Axiom catalog record for BPC-157/TB-4/Cartalax (component ratio 1); acceptance $\pm 10\%$ per Axiom SPEC-CONTENT-001

4 Sterility

Rapid Microbial DNA Screen (qPCR target panel)

Sterility · Rapid PCR: Target DNA not detected

No microbial target DNA detected

PASS

Sterility · Rapid PCR

PASS

Result

Target DNA not detected

Specification

Rapid PCR screen



8

Fentanyl Screen

LC-MS/MS targeted adulterant screen

Not detected

detection limit 1 ng/mg

PASSAnalytes
screened**Fentanyl, Acetylfentanyl, Acrylfentanyl, Butyrylfentanyl,
Carfentanil, Cyclopropylfentanyl, Furanylfentanyl,
Methoxyacetylfentanyl, ortho-Fluorofentanyl,
Valerylfentanyl, 4-ANPP (despropionyl fentanyl)**

Detection limit

1 ng/mg

Source container

A

A matching archived chromatogram is unavailable for this certificate.

Reporting Scope & Limitations**[Sterility · Rapid PCR]** DNA-target research screen only. It detects microbial DNA from viable and non-viable organisms alike, and is neither viable-CFU enumeration under USP <61> nor a batch sterility determination under USP <71>.**[Fentanyl Screen]** Targeted LC-MS/MS adulterant screen, reported as detected or not detected against its stated detection limit. A harm-reduction research screen, not an exhaustive adulterant panel.**Digital Signatures**

Analyst

Alana Reeves

Analyst Signature

ed25519:3c250da53d0378d238a5d5a1...

Technical Reviewer

Michael Niles

Reviewer Signature

ed25519:46e8f9b6bca2098fd0a75c8b...

Laboratory Director

Daniel Brennan

Director Signature

ed25519:3778b63ef07d23564418eaa3...

Current presentation note: The archived source assessment is incomplete or unavailable. This presentation does not establish physical instrument acquisition for those observations. This notice is outside the original signed certificate record. Where physical instrument analysis is performed, it takes place within Axiom Analytics' laboratory network, allocated at Axiom's discretion based on method, capacity, and order volume. Axiom Analytics performs sample accession, chain of custody, analytical oversight, and data review, and issues and is responsible for this certificate. Where analysis is subcontracted, the method is performed within the partner laboratory's published ISO/IEC 17025 scope of accreditation for that method, not merely at a laboratory holding ISO/IEC 17025 accreditation. Axiom Analytics does not itself currently hold ISO/IEC 17025 accreditation. The method-validation status of each reported result is identified beside that result. Partner laboratory identities are not disclosed: where samples are analyzed under double-blind conditions, they are identified only by an internal lot ID.

Each signature is an ed25519 signature over the SHA-384 hash of this report. Scan the QR on the letterhead or verify independently at <https://axiomanalyticslab.com/verify/AX-2026-3658-TPAT>.

Presentation corrected 2026-10-03; results and signatures unchanged.

✓ CRYPTOGRAPHICALLY SEALED (ed25519 + SHA-384)

SHA-384: 540cf69eb4272329b91ec1a4735152748a304d688cdde34a14b14e50cbe2881b...

Seal: ed25519:a88a2fd974ed5263d6691355a52b5be36294adf0...

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

RESEARCH USE ONLY. All analytical testing, validation reports, and interactive Certificates of Analysis (COAs) provided by Axiom Analytics are intended strictly for Research Use Only (RUO) in in-vitro or laboratory animal model environments. Axiom Analytics does not analyze, validate, evaluate, or make any representations regarding the safety, efficacy, toxicity, or legality of any tested substance for human or animal consumption, veterinary use, clinical diagnostics, food additives, cosmetics, or household applications.